198 related articles for article (PubMed ID: 27208558)
1. Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas.
Patin F; Crinière L; Francia T; Kassem S; Pierre P; Bruno C; Vayne C; Vourc'h P; Benz-de Bretagne I; Andres CR; Blasco H
Clin Biochem; 2016 Oct; 49(15):1205-1208. PubMed ID: 27208558
[No Abstract] [Full Text] [Related]
2. [Significance of 3-methoxytyramine urine measurement in the diagnosis of pheochromocytomas and paragangliomas: about 28 patients].
Le Jacques A; Abalain JH; Le Saos F; Carré JL
Ann Biol Clin (Paris); 2011; 69(5):555-9. PubMed ID: 22008135
[TBL] [Abstract][Full Text] [Related]
3. Deconjugated urinary metanephrine, normetanephrine and 3-methoxytyramine in laboratory diagnosis of pheochromocytoma and paraganglioma.
Bílek R; Zelinka T; Vlček P; Dušková J; Michalský D; Novák K; Bešťák J; Widimský J
Physiol Res; 2015; 64(Suppl 2):S313-22. PubMed ID: 26680494
[TBL] [Abstract][Full Text] [Related]
4. Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?
Peitzsch M; Kaden D; Pamporaki C; Langton K; Constantinescu G; Conrad C; Fliedner S; Sinnott RO; Prejbisz A; Därr R; Lenders JWM; Bursztyn M; Eisenhofer G
Eur J Endocrinol; 2020 May; 182(5):499-509. PubMed ID: 32187575
[TBL] [Abstract][Full Text] [Related]
5. Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management.
Foo SH; Chan SP; Ananda V; Rajasingam V
Singapore Med J; 2010 May; 51(5):e89-93. PubMed ID: 20593136
[TBL] [Abstract][Full Text] [Related]
6. Large dopamine-secreting pheochromocytoma: case report.
Awada SH; Grisham A; Woods SE
South Med J; 2003 Sep; 96(9):914-7. PubMed ID: 14513991
[TBL] [Abstract][Full Text] [Related]
7. Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.
Rao D; Peitzsch M; Prejbisz A; Hanus K; Fassnacht M; Beuschlein F; Brugger C; Fliedner S; Langton K; Pamporaki C; Gudziol V; Stell A; Januszewicz A; Timmers HJLM; Lenders JWM; Eisenhofer G
Eur J Endocrinol; 2017 Aug; 177(2):103-113. PubMed ID: 28476870
[TBL] [Abstract][Full Text] [Related]
8. Laboratory evaluation of pheochromocytoma and paraganglioma.
Eisenhofer G; Peitzsch M
Clin Chem; 2014 Dec; 60(12):1486-99. PubMed ID: 25332315
[TBL] [Abstract][Full Text] [Related]
9. Detection of spot urinary free metanephrines and 3-methoxytyramine with internal reference correction for the diagnosis of pheochromocytomas and paragangliomas.
Wang H; Zhang X; Zhen Q; Zou W; Chen H; Luo C; Ding M
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1156():122306. PubMed ID: 32829134
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis of hyperfunctioning adrenal masses].
Horger M; Fritz J; Bares R; Müssig K
Rofo; 2006 Dec; 178(12):1171-6. PubMed ID: 17396301
[No Abstract] [Full Text] [Related]
11. Comparison of plasma metanephrines measured by a commercial immunoassay and urinary catecholamines in the diagnosis of pheochromocytoma.
Christensen TT; Frystyk J; Poulsen PL
Scand J Clin Lab Invest; 2011 Dec; 71(8):695-700. PubMed ID: 22023043
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine.
Eisenhofer G; Goldstein DS; Sullivan P; Csako G; Brouwers FM; Lai EW; Adams KT; Pacak K
J Clin Endocrinol Metab; 2005 Apr; 90(4):2068-75. PubMed ID: 15644397
[TBL] [Abstract][Full Text] [Related]
13. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated
Eisenhofer G; Prejbisz A; Peitzsch M; Pamporaki C; Masjkur J; Rogowski-Lehmann N; Langton K; Tsourdi E; Pęczkowska M; Fliedner S; Deutschbein T; Megerle F; Timmers HJLM; Sinnott R; Beuschlein F; Fassnacht M; Januszewicz A; Lenders JWM
Clin Chem; 2018 Nov; 64(11):1646-1656. PubMed ID: 30097498
[TBL] [Abstract][Full Text] [Related]
14. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M
Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846
[TBL] [Abstract][Full Text] [Related]
15. Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
Eisenhofer G; Brown S; Peitzsch M; Pelzel D; Lattke P; Glöckner S; Stell A; Prejbisz A; Fassnacht M; Beuschlein F; Januszewicz A; Siegert G; Reichmann H
Ann Clin Biochem; 2014 Jan; 51(Pt 1):38-46. PubMed ID: 23873873
[TBL] [Abstract][Full Text] [Related]
16. High concentration of plasma methoxytyramine: dopamine-producing tumour or Parkinson's disease therapy?
Chtioui H; Sadowski SM; Winzeler B; Tschopp O; Grouzmann E; Abid K
Ann Clin Biochem; 2019 Jul; 56(4):466-471. PubMed ID: 30974961
[No Abstract] [Full Text] [Related]
17. Cardiac Dopamine-Secreting Paraganglioma with Involved Skull Base and Retroperitoneum After a History of Pheochromocytoma Post Adrenalectomy.
Hoo CE; Kuo CS; Huang CY; Huang PH; Yang AH; Hsu CP
Int Heart J; 2022; 63(4):786-792. PubMed ID: 35908855
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic Urine Profile: Searching for New Biomarkers of SDHx-Associated Pheochromocytomas and Paragangliomas.
Martins RG; Gonçalves LG; Cunha N; Bugalho MJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5467-5477. PubMed ID: 31504671
[TBL] [Abstract][Full Text] [Related]
19. Urinary dopamine in psychotic disorders is similar to that of pheochromocytoma and paraganglioma.
Brown JS
Schizophr Res; 2017 Mar; 181():70-71. PubMed ID: 27653463
[No Abstract] [Full Text] [Related]
20. Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.
Pamporaki C; Berends AMA; Filippatos A; Prodanov T; Meuter L; Prejbisz A; Beuschlein F; Fassnacht M; Timmers HJLM; Nölting S; Abhyankar K; Constantinescu G; Kunath C; de Haas RJ; Wang K; Remde H; Bornstein SR; Januszewicz A; Robledo M; Lenders JWM; Kerstens MN; Pacak K; Eisenhofer G
Lancet Digit Health; 2023 Sep; 5(9):e551-e559. PubMed ID: 37474439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
